Skip to main content
. 2025 Jan 28;27(4):531–536. doi: 10.4103/aja202499

Table 3.

Diagnostic performance of the clinical variables for clinically significant prostate cancer

Clinical variable AUC 95% CI Sensitivity (%) Specificity (%) P
PI-RADS 1–2
 Age 0.509 0.455–0.563 88.24 25.08 Reference
 BMI 0.561 0.507–0.614 41.18 83.69 0.624
 tPSA 0.612 0.559–0.663 76.47 54.08 0.166
 PV 0.789 0.742–0.830 88.24 61.03 0.005
 PSAD 0.843 0.801–0.880 88.24 80.06 <0.001
PI-RADS 3
 Age 0.577 0.499–0.652 33.33 83.80 Reference
 BMI 0.513 0.435–0.591 77.78 11.27 0.437
 tPSA 0.591 0.513–0.666 44.44 78.87 0.847
 PV 0.808 0.740–0.864 85.19 68.31 0.004
 PSAD 0.775 0.704–0.835 85.19 59.15 0.009
All patients
 Age 0.553 0.509–0.597 97.73 12.05 Reference
 BMI 0.531 0.487–0.575 27.27 87.74 0.761
 tPSA 0.611 0.567–0.653 72.73 48.63 0.270
 PV 0.794 0.756–0.828 84.09 65.12 <0.001
 PSAD 0.806 0.769–0.839 77.27 73.36 <0.001

PI-RADS: Prostate Imaging Reporting and Data System; BMI: body mass index; tPSA: total prostate-specific antigen; PV: prostate volume; PSAD: prostate-specific antigen density; AUC: area under curve; 95% CI: 95% confidence interval